Contrary to the decade-long trend of outsourcing to CDMOs, major pharmaceutical companies are now vertically re-integrating their supply chains. Driven by supply chain vulnerabilities, they now view manufacturing not as a cost center but as a strategic advantage, creating opportunities for technology enablers rather than just capacity providers.

Unlike small-molecule drugs, biologics manufacturing cannot be simply scaled up on demand because "the process is the product." A superior manufacturing and supply chain capability is not a back-office function but a key market differentiator that commercial teams must leverage to win customers and outpace competitors.

The medtech industry is uniquely squeezed by tariffs, inflation, and an inability to raise prices, crushing margins and valuations. This financial pressure has driven stock multiples to near all-time lows, signaling a major acquisition opportunity for private equity firms.

Years ago, MedTech M&A was driven by acquiring revenue and customer lists. Today, the priority has shifted to acquiring scarce, specialized technical capabilities and regulatory infrastructure that are difficult and time-consuming to build internally, signaling a major evolution in valuation drivers.

A successful acquisition strategy goes beyond the highest bid. It involves 'thinking like the molecule'—evaluating which buyer has the specific expertise, capabilities, and cultural alignment to best steward the asset's development. This reframes M&A from a financial transaction to a decision about the asset's future.

A confluence of factors is driving M&A toward Contract Development and Manufacturing Organizations (CDMOs). Capital is loosening as interest rates fall, a decade of private equity investments are maturing, pharma-device convergence (e.g., GLP-1s) is increasing, and geopolitical pressures encourage onshoring.

The current MedTech M&A market is a virtuous cycle feeding itself. Private Equity exits of mature CDMO platforms provide acquisition targets for OEMs. Simultaneously, OEM carve-outs of non-core manufacturing assets create new platform investment opportunities for PE firms.

Regulatory readiness is one of the most underappreciated value drivers in MedTech M&A. An acquirer will pay a premium for a target with a mature regulatory infrastructure, as this "organizational muscle" can save them 2-3 years versus building it from scratch.

The primary challenge for many MedTech innovations is not the initial science but translating a lab process into a robust, scalable, and GMP-compliant manufacturing system. This requires a shift from proving a concept to ensuring consistent quality and patient safety.